

BIOSPECIFICS TECHNOLOGIES CORP
 Form 4
 May 19, 2016

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Wegman Thomas

2. Issuer Name and Ticker or Trading Symbol
 BIOSPECIFICS TECHNOLOGIES CORP [BSTC]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
 05/18/2016

Director 10% Owner
 Officer (give title below) Other (specify below)
 President

C/O BIOSPECIFICS TECHNOLOGIES CORP., 35 WILBUR STREET

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

LYNBROOK, NY 11563

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)		
			Code	V	Amount or Price (A) or (D)				
Common Stock, \$0.001 par value	05/18/2016		S ⁽¹⁾		50	D	\$ 33.8 ⁽¹⁾ 1,005,128	I	See footnote ⁽⁵⁾
Common Stock, \$0.001 par value	05/18/2016		S ⁽²⁾		150	D	\$ 34.14 ⁽²⁾ 1,004,978	I	See footnote ⁽⁵⁾
Common Stock,	05/18/2016		S ⁽³⁾		50	D	\$ 34.11 1,004,928	I	See footnote

Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 4

\$0.001 par value					(3)			(5)
Common Stock, \$0.001 par value	05/18/2016	S(4)	24,750	D	\$ 33 (4)	980,178	I	See footnote (5)
Common Stock, \$0.001 par value	05/18/2016	S(6)	50	D	\$ 33.8 (6)	220,772	D	
Common Stock, \$0.001 par value	05/18/2016	S(7)	150	D	\$ 34.14 (7)	220,622	D	
Common Stock, \$0.001 par value	05/18/2016	S(8)	50	D	\$ 34.11 (8)	220,572	D	
Common Stock, \$0.001 par value	05/18/2016	S(9)	24,750	D	\$ 33 (9)	195,822	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned (Instr. 6)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Wegman Thomas C/O BIOSPECIFICS TECHNOLOGIES CORP., 35 WILBUR STREET LYNBROOK, NY 11563	X	X	President	

Signatures

/s/ Carl A. Valenstein, attorney-in-fact for Thomas Wegman

05/19/2016

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The selling price of \$33.80 is reflective of the sale price of all transactions reported on this line.
- (2) The selling price of \$34.14 is reflective of the sale price of all transactions reported on this line.
- (3) The selling price of \$34.11 is reflective of the sale price of all transactions reported on this line.
- (4) The selling price of \$33.00 is reflective of the sale price of all transactions reported on this line.

These shares are held in trust on behalf of the reporting person and Mrs. Toby Wegman. The reporting person is the co-trustee of the trust with Ms. Toby Wegman. The reporting person disclaims beneficial ownership of the shares held by the trust except to the extent of the reporting person's pecuniary interest therein.

- (6) The selling price of \$33.80 is reflective of the sale price of all transactions reported on this line.
- (7) The selling price of \$34.14 is reflective of the sale price of all transactions reported on this line.
- (8) The selling price of \$34.11 is reflective of the sale price of all transactions reported on this line.
- (9) The selling price of \$33.00 is reflective of the sale price of all transactions reported on this line.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.